Misc – Page 4 – GeneLit

Exceptional behavior of breast cancer-associated type 1 gene in breast invasive carcinoma.
Abbas Z, Nouroz F, Ejaz S.
J Cancer Res Ther. 2022 Oct-Dec;18(6):1743-1753. doi: 10.4103/jcrt.JCRT_1310_20.

Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M, Yanagida S, Iwamoto M, Kiyokawa T, Chiba N, Okamoto A.
Gynecol Oncol. 2022 Nov 17;168:83-91. doi: 10.1016/j.ygyno.2022.11.006. Epub ahead of print.

3D CRISPR Screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction.
Zhang H, Gao H, Gu Y, John A, Wei L, Huang M, Yu J, Adeosun A, Weinshilboum R, Wang L.
Front Oncol. 2022 Nov 14;12:999302. doi: 10.3389/fonc.2022.999302.

Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors.
Golder A, Nelson L, Tighe A, Barnes B, Coulson-Gilmer C, Morgan RD, McGrail JC, Taylor SS.
NAR Cancer. 2022 Nov 12;4(4):zcac036. doi: 10.1093/narcan/zcac036.

LitAlert ~~ GeneLit.com

Noninvasive Pregestational Genetic Testing of Embryos Using Smart Sensors Array.
Abu Raya YS, Srebnik N, Rubinstein E, Schonberger O, Broza YY, Suschinel R, Haick H, Ionescu R.
ACS Sens. 2022 Nov 14. doi: 10.1021/acssensors.2c01492. Epub ahead of print.

Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation.
Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernado-Morales C, Haro N, Giles FJ, Pozo OJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV.
Clin Cancer Res. 2022 Nov 14:CCR-22-2551. doi: 10.1158/1078-0432.CCR-22-2551. Epub ahead of print.

DNA Repair Mechanisms, Protein Interactions and Therapeutic Targeting of the MRN Complex.
McCarthy-Leo C, Darwiche F, Tainsky MA.
Cancers (Basel). 2022 Oct 27;14(21):5278. doi: 10.3390/cancers14215278.

Replicative Instability Drives Cancer Progression.
Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW.
Biomolecules. 2022 Oct 26;12(11):1570. doi: 10.3390/biom12111570.

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.
Smith HL, Willmore E, Mukhopadhyay A, Drew Y, Curtin NJ.
Cancers (Basel). 2022 Nov 12;14(22):5559. doi: 10.3390/cancers14225559.

Partial Reduction in BRCA1 Gene Dose Modulates DNA Replication Stress Level and Thereby Contributes to Sensitivity or Resistance.
Classen S, Rahlf E, Jungwirth J, Albers N, Hebestreit LP, Zielinski A, Poole L, Groth M, Koch P, Liehr T, Kankel S, Cordes N, Petersen C, Rothkamm K, Pospiech H, Borgmann K.
Int J Mol Sci. 2022 Nov 1;23(21):13363. doi: 10.3390/ijms232113363.

Signal "on-off-off" strategy for improving the sensitivity of BRCA1 electrochemical detection by combining gold substrate amplification, DNA conformational transformation and DSN enzymatic hydrolysis dual reduction.
Li Z, Chen J, Zhang L, Liu Y, Jia Y, Zhou G, Luo L.
Anal Chim Acta. 2022 Dec 1;1235:340461. doi: 10.1016/j.aca.2022.340461. Epub 2022 Oct 1.

Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51.
Heijink AM, Stok C, Porubsky D, Manolika EM, de Kanter JK, Kok YP, Everts M, de Boer HR, Audrey A, Bakker FJ, Wierenga E, Tijsterman M, Guryev V, Spierings DCJ, Knipscheer P, van Boxtel R, Ray Chaudhuri A, Lansdorp PM, van Vugt MATM.
Nat Commun. 2022 Nov 7;13(1):6722. doi: 10.1038/s41467-022-34519-8.

Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers.
Ren J, Quan X, Liu Y, Li J, Zhang X, Li Z, Zhang X.
Bioorg Med Chem Lett. 2022 Nov 4:129046. doi: 10.1016/j.bmcl.2022.129046. Epub ahead of print.

Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
Mizrahi AG, Hamad H, Gugenheim A, Nisman B, Kuznetz A, David IB, Gelfend Y, Cohen S, Zick A, Sheva K, Nechushtan H, Peretz T, Meirovitz A.
Anticancer Res. 2022 Nov;42(11):5257-5263. doi: 10.21873/anticanres.16032.

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Coelho R, Tozzi A, Disler M, Lombardo F, Fedier A, López MN, Freuler F, Jacob F, Heinzelmann-Schwarz V.
Cell Death Dis. 2022 Oct 28;13(10):909. doi: 10.1038/s41419-022-05347-x.

Common germline risk variants impact somatic alterations and clinical features across cancers.
Namba S, Saito Y, Kogure Y, Masuda T, Bondy ML, Gharahkhani P, Gockel I, Heider D, Hillmer A, Jankowski J, MacGregor S, Maj C, Melin B, Ostrom QT, Palles C, Schumacher J, Tomlinson I, Whiteman DC, Okada Y, Kataoka K.
Cancer Res. 2022 Oct 26:CAN-22-1492. doi: 10.1158/0008-5472.CAN-22-1492. Epub ahead of print.

TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
Khaled NB, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN.
Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240.

PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination.
Pei X, Mladenov E, Soni A, Li F, Stuschke M, Iliakis G.
Int J Mol Sci. 2022 Oct 25;23(21):12876. doi: 10.3390/ijms232112876.